|
Jul 30
|
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
|
|
Jul 23
|
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
|
|
Jul 21
|
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
|
|
Jul 16
|
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
|
|
Jul 1
|
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
|
|
Jun 4
|
NanoViricides Measles Drug Development Animal Study is Imminent
|
|
May 22
|
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
|
|
May 16
|
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
|
|
May 15
|
NanoViricides: Fiscal Q3 Earnings Snapshot
|
|
May 14
|
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
|
|
Mar 4
|
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
|
|
Feb 14
|
NanoViricides: Fiscal Q2 Earnings Snapshot
|
|
Feb 14
|
Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In?
|
|
Feb 11
|
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
|